Urabrelimab

DB17209InvestigationalProtein Based Therapies

Urabrelimab: Overview.

Mechanism: Pharmacologically active on Low affinity immunoglobulin gamma Fc region receptor II-a and Leukocyte surface antigen CD47
Curator reviewed
Also known as: Immunoglobulin igg4, anti-(human cd47) (human monoclonal srf231 .gamma.4-chain), disulfide with human monoclonal srf231 .kappa.-chain, dimer
Code names: SRF-231

Resolves to

Compound

Targets

What you can answer from here — as of July 08, 2026

2Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

1Clinical trialPhase, status and sponsor resolved per trial

3+ReferencesStructured and connected to the statements they support

Which drugs share a target with Urabrelimab, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.